Dr. Antonio Calles 🫁🚭 Profile picture
Medical Oncology 🏥 Hospital General Universitario Gregorio Marañón & @RuberInter ⎪@myESMO Faculty 🫁 ⎪#endlungcancer #lcsm

Aug 12, 2021, 11 tweets

Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer in: Journal of the National Comprehensive Cancer Network. #lcsm #immunonc jnccn.org/view/journals/…

Durvalumab + chemotherapy resulted in an additional 0.27 LYs and 0.20 QALYs, resulting in an ICER of $464,711.90 per QALY versus the chemotherapy treatment. The cost of durvalumab has the greatest influence on this model. More mature follow-up needed for a more stable model, tho.

Subgroup analyses showed that the ICER remained higher than $150,000/QALY (the willingness-to-pay threshold in the United States) across all patient subgroups. #lcsm #immunonc

These results are in line with the previously published analysis from IMpower-133. The cost of atezolizumab has the greatest effect on the results. Therefore, first-line chemo-immunotherapy for unselected population doesn’t seem to be cost-effective from the US perspective. #lcsm

Here it is the publication.
Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. #lcsm #immunonc
lungcancerjournal.info/article/S0169-…

Atezolizumab plus chemotherapy was estimated to increase costs by $52,881 compared with chemotherapy alone, with a gain of 0.10 quality adjusted life years (QALYs), leading to an incremental cost-effective ratio of $528,810 per QALY. #lcsm #immunonc

Costs apart (they vary upon region), What is the magnitude of clinical benefit of atezolizumab and durvalumab for the treatment of patients with small-cell lung cancer? According to ESMO-MCBS score, not that much. Both agents score 3 in a 5 point scale. #lcsm

Durvalumab ESMO-MCBS scorecard from CASPIAN trial.
esmo.org/guidelines/esm…

Atezolizumab ESMO-MCBS scorecard from IMpower-133 trial.
esmo.org/guidelines/esm…

So, based on the information above, how much are you willing to pay for either atezolizumab or durvalumab for the treatment of patients with ES-SCLC in your jurisdiction?
(costs in $ per patient/year) #lcsm

Share this Scrolly Tale with your friends.

A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.

Keep scrolling